Stories about Krankheit
- One documentmore
European Alliance Against Depression
First European Patient Congress Depression for those affected by depression and their close relations takes place online on December 7, 2024 / Free online-event offers information and experience-sharing
Frankfurt am Main (ots) - The European Patient Congress Depression, hosted by the European Alliance Against Depression (EAAD), will take place on December 7, 2024. This free online-event is designed to support individuals affected by depression and their relatives, providing a platform for expert guidance, patient ...
moreInceptor Regulates Insulin Homeostasis: A New Approach for Diabetes Therapies
moreLast Call for canSERV Third Open Call Funding
One documentmoreGrünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...
moreFirst participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...
more
Event Announcement: VIROFIGHT Hybrid Symposium
One documentmorePress Release: EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar
EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...
moreExtreme Rainfall Poses Health Risks
Extreme Rainfall Poses Health Risks An international study led by Helmholtz Munich investigates the health consequences of heavy rainfall events. Researchers analyzed the relationship between precipitation patterns and mortality rates at 645 locations across 34 countries from 1980 to 2020. The key finding: Extremely heavy rainfall, which occurs approximately every five years, significantly increases the risk of death, ...
moreRHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU
moreLaunch of canSERV Call for Service Provision – "Training the Next Generation of Cancer Researchers"
One documentmore- 2
Fundació Puigvert validates a new tool capable of selecting the most suitable antibiotic for uncomplicated urinary tract infections within 45 minutes.
One documentmore
- 2
Record financing rounds at the Munich biotech hub
One documentmore Bosch Healthcare Solutions GmbH
Near-patient PCR rapid test for whooping cough for Vivalytic by Bosch now available / World's first fully automated PCR test for detection of B. pertussis, B. parapertussis, B. holmesii
morecanSERV relaunches Open Call for Service Provision
One documentmorePress release: STADA continues strong growth journey in the first half of 2024
One documentmoreBosch Healthcare Solutions GmbH
PCR rapid test for 3 important gastroenteritis pathogens for Vivalytic by Bosch now available / World’s first fully automated PCR test for detection of C. difficile, norovirus, and rotavirus at the sampling point
morecanSERV to Accelerate Your Cancer Research - 2 Calls for Service Provision Open
2 Documentsmore
- 4
Sysmex’s PA-100 AST System Wins One of the UK’s Biggest Science Prizes
One documentmore Press release: Alvotech and STADA add to strategic alliance through denosumab partnership
Alvotech and STADA add to strategic alliance through denosumab partnership - STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle ...
One documentmoreNew Study: Father's Diet Before Conception Influences Children's Health
morePress release: STADA welcomes CHMP positive opinion on extending indication for Kinpeygo
STADA welcomes CHMP positive opinion on extending indication for Kinpeygo - The CHMP adopted a positive opinion recommending a change to the terms of the marketing authorization of Kinpeygo for the treatment of adults with primary immunoglobulin A, now covering patients with a UPCR of ≥0.8 g/g - ...
One documentmorePress Release: Restless Legs Syndrome: Genetic Discoveries Advance Treatment and Risk Prediction
Researchers at Helmholtz Munich and the Technical University of Munich (TUM) together with international collaborators have conducted the largest genetic investigation of the restless legs syndrome to date. Their findings, ...
morePress release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...
One documentmore
canSERV invites applications for "Revolutionising Cancer Patient Care"
One documentmore- 3
canSERV invites applications for "Revolutionising Cancer Patient Care"
One documentmore Technische Universität München
Multi-purpose mucus - What mucins can do in medicine
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE What mucins can do in medicine Multi-purpose mucus They are in our eyes, on our tongues, and in our stomachs: Protective layers of mucus, a slime consisting primarily of mucins. These are molecules which bind water to form a natural lubricant. Researchers at the Technical University of Munich (TUM) use them to develop coatings for contact lenses and intubation tubes, healing ...
moreNew Study: Night-time heat significantly increases the risk of stroke
moreBosch Healthcare Solutions GmbH
PCR rapid test for Candida auris for Vivalytic by Bosch now available / World’s first fully automated PCR test for detection of the multidrug-resistant fungus at the point of care
Waiblingen (ots) - - Vivalytic test detects Candida auris in under an hour at the point of care, making it the world’s first test suitable for screenings. - Candida auris infection rates are on the rise in Germany and can cause severe infections, for example of the bloodstream (sepsis). - Hospitals can use the new ...
moreLAST CHANCE: canSERV Second Open Call for Cancer Research Service Provision
One documentmore